Jci_page_head_homepage_01 Jci_page_head_homepage_02
Daniel R. Clayburgh, Terrence A. Barrett, Yueming Tang, Jon B. Meddings, Linda J. Van Eldik, D. Martin Watterson, Lane L. Clarke, Randall J. Mrsny, Jerrold R. Turner
Published in Volume 115, Issue 10
J Clin Invest. 2005; 115(10):2702–2715 doi:10.1172/JCI24970
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 9

Treatment of intestinal epithelium with the MLCK inhibitor PIK. (A) The distribution of biotinylated stable PIK after perfusion of a segment of small intestine was detected using fluorescently tagged streptavidin (red). F-actin (green) and DNA (blue) are superimposed in the right panel for orientation. Perfused PIK was present in villous (V) and crypt (C) epithelia but was not seen within the lamina propria, muscularis mucosa, or submucosa (scale bars, 25 μm). (B) H&E-stained section of anti-CD3–treated intestine with and without PIK treatment showed no evidence of toxicity related to PIK treatment (scale bars, 100 μm). (C) Mucosal IFN-γ transcription was markedly increased 3 hours after anti-CD3 injection in both PIK-treated and untreated mice (n = 3). (D) Mucosal TNF-α transcription was markedly increased 3 hours after anti-CD3 injection in both PIK-treated and untreated mice (n = 3). (E) Western blot analysis of epithelial MLC phosphorylation revealed that the addition of 250 μM PIK to the luminal perfusate reduced baseline epithelial MLC phosphorylation and also prevented the large increase in MLC phosphorylation induced 3 hours after anti-CD3 injection.